Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRINOX3 in Advanced/Metastatic Pancreatic Cancer
NCT05988814Phase 2Recruiting
- Sponsor
- Centre Georges-François Leclerc
- Start
- Jan 2024
- Primary completion
- Jul 2029
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, irinotecan, oxaliplatin and folinic acid in pancreatic cancer (PC), sponsored by Centre Georges-François Leclerc. Primary endpoint: Progression-Free Survival at 6 months. Started Jan 2024; status: recruiting.
02
Drugs
fluorouracilirinotecanoxaliplatinfolinic acid
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05988814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05988814.